Valneva to Present on Chikungunya at Several Leading Scientific Conferences
11 Outubro 2023 - 12:45PM
Saint-Herblain (France), October 11, 2023 –
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
company, announces today it will present on the mosquito-borne
chikungunya disease at several leading scientific conferences
during the fourth quarter of 2023.
At IDWeek, the annual meeting
of the Infectious Diseases Society of America
(IDSA), Valneva will support the roundtable discussion
“Chikungunya is an Increasing Global Threat: The Need for Better
Protection” taking place on October 14, 2023 at 6:00 pm Eastern
Daylight Time (EDT) in Boston, Massachusetts.
At the American Society of Tropical
Medicine and Hygiene (ASTMH) 2023 Annual Meeting in
Chicago, Illinois, Valneva will hold two chikungunya presentations
on October 20, 2023 at 11:00 am and 12:15 pm Central Daylight Time
(CDT). The Company will also display three posters: “Clinical
evidence on disease burden of the mosquito-borne chikungunya virus
(CHIKV): a systematic literature review”, “The economic Burden of
Illness of the globally spreading chikungunya virus (CHIKV): a
Systematic Literature Review” and “The spread of chikungunya
vectors: a potential threat to global health.”
During the World Vaccine Congress
Europe taking place October 16 - 19, 2023 in Barcelona,
Spain, Valneva will display a poster titled “Safety of Live
Attenuated Vaccines in Immunocompromised Patients and Pregnant
Women: A Systematic Review”.
At the International Society of
Vaccines Annual Congress taking place in
Lausanne, Switzerland Valneva will present on chikungunya on
October 24, 2023 at 09:45 am Central European Summer Time (CEST).
The Company will also display two posters at the event, including
“Dynamic disease transmission model recreating the 2017 Chikungunya
virus (CHIKV) outbreak in Anzio, Italy: the impact of vaccination,
global warming, and viral importation.”
Finally, during the International
Society for Pharmacoeconomics and Outcomes Research (ISPOR)
European Congress taking place November 12 - 15, 2023 in
Copenhagen, Denmark, Valneva will display three posters titled:
“Global Burden of Disease Study on Chikungunya: Estimating
Disability-Adjusted Life Years (DALYs) and Cost Burden”, “A
systematic literature review and meta-analysis of clinical
chikungunya outcomes” and “Transmission Dynamics and Vaccination
Strategies for Chikungunya Virus (CHIKV): An Outbreak Simulation
Study in Rome, Italy.”
About ChikungunyaChikungunya is
a mosquito-borne viral disease caused by the chikungunya virus
(CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes.
Infection leads to symptomatic disease in up to 97% of humans after
four to seven days following the mosquito bite. While mortality
with CHIKV is low, morbidity is high, and the global market for
vaccines against chikungunya is estimated to exceed $500 million
annually by 20321. Clinical symptoms include acute onset of fever,
debilitating joint and muscle pain, headache, nausea, rash and
chronic arthralgia. Chikungunya virus often causes sudden large
outbreaks with high attack rates, affecting one-third to
three-quarters of the population in areas where the virus is
circulating. The high-risk areas of infection for travelers are
places where chikungunya virus-carrying mosquitos are endemic,
including the Americas, parts of Africa, and Southeast Asia, and
the virus has spread to more than 110 countries2. As of July 2022,
more than three million cases have been reported in the Americas3
and the economic impact is considered to be significant. The
medical and economic burden is expected to grow as the CHIKV
primary mosquito vectors continue to spread geographically. There
are no preventive vaccines or effective treatments available and,
as such, chikungunya is considered to be a major public health
threat.
About Valneva SEValneva is a
specialty vaccine company focused on the development, manufacturing
and commercialization of prophylactic vaccines for infectious
diseases with significant unmet medical need. The Company takes a
highly specialized and targeted approach to vaccine development and
then applies its deep understanding of vaccine science to develop
prophylactic vaccines addressing these diseases. Valneva has
leveraged its expertise and capabilities both to commercialize
three vaccines and to rapidly advance a broad range of vaccine
candidates into and through the clinic, including candidates
against the chikungunya virus and Lyme disease.
Valneva
Investor and Media ContactsLaetitia Bachelot-FontaineVP
Global Communications & European Investor RelationsM +33 (0)6
4516
7099laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing, results and
completion of research, development and clinical trials for product
candidates, to regulatory approval of product candidates and review
of existing products. In addition, even if the actual results or
development of Valneva are consistent with the forward-looking
statements contained in this press release, those results or
developments of Valneva may not be sustained in the future. In some
cases, you can identify forward-looking statements by words such as
“could,” “should,” “may,” “expects,” “anticipates,” “believes,”
“intends,” “estimates,” “aims,” “targets,” or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
and delays involved in the development and manufacture of vaccines,
unexpected clinical trial results, unexpected regulatory actions or
delays, competition in general, currency fluctuations, the impact
of the global and European credit crisis, and the ability to obtain
or maintain patent or other proprietary intellectual property
protection. Success in preclinical studies or earlier clinical
trials may not be indicative of results in future clinical trials.
In light of these risks and uncertainties, there can be no
assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
1 VacZine Analytics Chikungunya virus vaccines Global demand
analysis. February 20202
https://www.who.int/news-room/fact-sheets/detail/chikungunya3
PAHO/WHO data: Number of reported cases of chikungunya fever in the
Americas (Cumulative Cases 2018-2022 and Cases per year 2013-2017).
https://www.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-weekly-en.html.
Last accessed 25 Jul 2022.
- 2023_10_11_Chik_Q4_Conference_Presentations_PR_EN
Valneva (EU:VLA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Valneva (EU:VLA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024